CytoDyn Announces Settlement with Amarex Clinical Research LLC
09 juil. 2024 08h30 HE
|
CytoDyn Inc.
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 ...
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
27 juin 2024 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn to Host Webcast to Provide Company Update
28 mai 2024 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
May 2024 Letter to Shareholders
16 mai 2024 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024...
CytoDyn Announces FDA Has Lifted Clinical Hold
29 févr. 2024 08h30 HE
|
CytoDyn Inc.
Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company...
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
01 févr. 2024 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
29 janv. 2024 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Announces Webcast to Provide Company Update
07 déc. 2023 16h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
21 nov. 2023 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
November 2023 Letter to Shareholders
03 nov. 2023 16h02 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of...